Yahoo · Oct 30, 2026
Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
Mastercard, Cheniere Energy and Viatris shares climbed to annual highs on Thursday amid strong quarterly results and positive company catalysts.
NYSE · VTRS
Viatris Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$18.92
Up+$0.12 (+0.61%)
Updated Nov 4, 2026, 7:24 PM
SID Score
7.5/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 13.35B
- P/E ratio
- -3.66
- Dividend yield
- 2.54%
- 52-week range
- $12.37 – $19.51
- Volume
- 7.56M
- Avg. volume
- 9.37M
Price performance · VTRS
VTRS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
VTRS closed at $18.92 after 21 trading sessions, up 7.87% for the selected period.
- Last close
- $18.92
- Period change
- +7.87%
- Period low
- $17.25
- Period high
- $19.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $18.70 | $18.94 | $18.64 | $18.92 | 7.56M |
| Nov 2, 2026 | $19.06 | $19.12 | $18.65 | $18.67 | 7.25M |
| Oct 30, 2026 | $19.29 | $19.505 | $19.00 | $19.035 | 8.79M |
| Oct 29, 2026 | $18.97 | $19.23 | $18.93 | $19.20 | 10.49M |
| Oct 28, 2026 | $18.535 | $18.93 | $18.46 | $18.77 | 7.85M |
| Oct 27, 2026 | $18.19 | $18.83 | $18.17 | $18.72 | 6.07M |
| Oct 26, 2026 | $18.20 | $18.395 | $18.11 | $18.29 | 6.06M |
| Oct 23, 2026 | $18.33 | $18.3805 | $17.86 | $18.00 | 7.22M |
| Oct 22, 2026 | $18.45 | $18.66 | $18.345 | $18.48 | 5.44M |
| Oct 21, 2026 | $18.64 | $18.695 | $18.43 | $18.45 | 10.19M |
| Oct 20, 2026 | $18.34 | $18.685 | $18.285 | $18.65 | 14.27M |
| Oct 19, 2026 | $18.625 | $18.7502 | $18.175 | $18.26 | 11.53M |
| Oct 16, 2026 | $18.20 | $18.665 | $18.15 | $18.655 | 9.42M |
| Oct 15, 2026 | $17.75 | $18.235 | $17.7001 | $18.22 | 8.39M |
| Oct 14, 2026 | $17.27 | $17.82 | $17.24 | $17.44 | 8.68M |
| Oct 13, 2026 | $17.66 | $17.66 | $17.205 | $17.25 | 7.55M |
| Oct 12, 2026 | $17.70 | $17.79 | $17.525 | $17.54 | 7.55M |
| Oct 9, 2026 | $17.36 | $17.755 | $17.185 | $17.64 | 8.83M |
| Oct 8, 2026 | $17.26 | $17.52 | $16.89 | $17.44 | 14.11M |
| Oct 7, 2026 | $17.52 | $17.815 | $17.41 | $17.49 | 7.54M |
| Oct 6, 2026 | $17.77 | $17.87 | $17.31 | $17.54 | 6.68M |
Latest VTRS news
The latest Smart Investors Daily articles mentioning VTRS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VTRS research
Overview
Company profile and research snapshot.
Company profile
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $15.00
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Neutral | — |
| Oct 21, 2026 | JP Morgan | Neutral | — |
| Oct 5, 2026 | UBS | Buy | — |
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Sep 16, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
RYZUMVI Approval Could Be A Key Test For Viatris Stock (VTRS)
Viatris received FDA approval in October 2026 to expand RYZUMVI ophthalmic solution 0.75% for treating presbyopia in adults, adding to its existing indication for pharmacologically induced mydriasis and supported by a defined safety profile from clinical trials. This broader eye care use case strengthens Viatris' presence in ophthalmology, connecting a nearly universal age related condition to an already commercialized product with established prescribing guidance and usage precautions. We...
Yahoo · Oct 28, 2026
Viatris (VTRS) Wins FDA Approval For RYZUMVI In Adult Presbyopia
Viatris (NasdaqGS: VTRS) received U.S. FDA approval for RYZUMVI to treat presbyopia in adults in October 2026. RYZUMVI was previously cleared only for pharmacologically induced mydriasis, so the new label adds a second approved use. Presbyopia affects many adults as they age, which broadens the addressable patient pool for Viatris' ophthalmology franchise. The expanded RYZUMVI presbyopia indication is important, but investors should weigh it alongside other Viatris developments. Take a look...
Yahoo · Oct 27, 2026
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
